Werewolf Therapeutics Inc

NASDAQ HOWL

Data sourced from

and

Download Data

Werewolf Therapeutics Inc Free Cash Flow to Equity (FCFE) 1 year YoY Change (%) for the year ending September 20, 2024

Werewolf Therapeutics Inc Free Cash Flow to Equity (FCFE) 1 year YoY Change (%) is NA for the year ending September 20, 2024. Free Cash Flow to Equity represents the cash flow available to equity shareholders after accounting for capital expenditures and net acquisitions. It indicates the amount of cash flow that can be distributed to shareholders or reinvested in the business. It is useful in assessing the company's ability to generate cash flow for its equity investors. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: HOWL

Werewolf Therapeutics Inc

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Key trends